Status:

COMPLETED

Evaluation of the Analytical Performance of ALLEGRO™ Instrument

Lead Sponsor:

Nova Biomedical

Conditions:

Diabetes Mellitus

Kidney Diseases

Eligibility:

All Genders

18+ years

Brief Summary

To assess the performance of the Allegro in the hands of CLIA-Waived Point-of-Care users in at least three distinct Point-of-Care clinical settings and compare the performance characteristics to other...

Detailed Description

Blood and urine tests are used in the assessment of diabetes and to guide clinical management. In the traditional model of care, blood samples are taken from patients at the clinic and are sent to the...

Eligibility Criteria

Inclusion

  • patients with ordered HbA1c, lipid profile, and UACr

Exclusion

  • pediatric

Key Trial Info

Start Date :

March 25 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 15 2021

Estimated Enrollment :

628 Patients enrolled

Trial Details

Trial ID

NCT04096313

Start Date

March 25 2020

End Date

December 15 2021

Last Update

December 16 2021

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Health Awareness, Inc

Jupiter, Florida, United States, 33458

2

South Florida Research Organization

Medley, Florida, United States, 33166

3

Health Awareness, Inc PSL

Port Saint Lucie, Florida, United States, 34952

Evaluation of the Analytical Performance of ALLEGRO™ Instrument | DecenTrialz